The latest trading day saw Moderna (MRNA) settling at $245.81, representing a +1.54% change from its previous close.

Moderna is one of the hottest stocks of the year because of its custom cancer treatment. Full Phase 3 data are set to be ...

Moderna shares rose ahead of late-stage clinical trial results for intismeran autogene.The companies are preparing regulatory ...

Moderna (NASDAQ: MRNA) leaped into the spotlight during the early days of the pandemic, and that was because the up-and-coming biotech player had a solution to the problem: a vacc ...

Moderna and Merck prepare FDA submission for their individualized mRNA melanoma vaccine.The company reported an annual ...

A new flu vaccine using messenger RNA technology is available at some King Soopers pharmacies in Colorado, offering adults 50 ...

What Happened? A number of stocks jumped in the afternoon session after investors rotated into defensive assets and priced in ...

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was ...

Researchers redesigned lipid nanoparticles to cut liver accumulation of locally injected mRNA by up to eighty-fold in mice ...

A study by Australian researchers compared three mRNA-LNP vaccine platforms in human blood samples, generating findings that ...

Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the ...